Nasdaq

Natera Awarded Advanced Diagnostic Laboratory Test (ADLT) Status for its Signatera® MRD Test From CMS

AUSTIN, Texas, June 18, 2021 /PRNewswire/ -- Natera,Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that the Centers for Medicare & Medicaid Services (CMS) ...
Nasdaq

New Study Validates the Signatera® MRD Test and Demonstrates its Clinical Utility in Early-Stage Esophageal Cancer

AUSTIN, Texas, July 28, 2021 /PRNewswire/ -- Natera,Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced a new peer-reviewed paper published in Gastroenterology ...
Business Wire

Medicare Extends Coverage of Natera’s Signatera™ MRD Test to Breast Cancer

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it has received written confirmation from the Centers for Medicare & ...
Business Insider

New Results From the Landmark Prospective CIRCULATE Trial Expand Clinical Utility of the Signatera® MRD Test in Colorectal Cancer

AUSTIN, Texas, July 2, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new data on its personalized and ...
Business Wire

New MRD Publication in Unresectable Stage I-III Lung Cancer Demonstrates Signatera’s Ability to Risk Stratify and Detect Progression Early

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in Frontiers in Oncology demonstrating the ability of ...
Seeking Alpha

Natera Announces Publication of Signatera™ Analysis from Randomized, Phase III CALGB (Alliance)/SWOG 80702 Study in Colorectal Cancer

JAMA Oncology study highlights that Signatera-positive patients treated with celecoxib and conventional chemotherapy experienced a >40% reduction in risk of death, whereas Signatera-negative patients ...
Seeking Alpha

Signatera™ Test Selected for NRG-Sponsored Phase III ARCHER Trial in Bladder Cancer

Randomized study aims to reduce treatment burden for patients and utilizes Signatera to monitor for disease recurrence AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NTRA) (NASDAQ: NTRA), a global ...
Hosted on MSN

Natera initiates trial of Signatera test for breast cancer

Natera has announced the initiation of the Phase II TEODOR trial of its Signatera test aimed at replacing chemotherapy with endocrine therapy before surgery in certain breast cancer patients. The ...
Cure Today

This Test Helped Identify Treatment in Colorectal Cancer Surgery

Stage 3 colorectal cancer patients with MRD benefit from Celebrex addition to chemotherapy, showing a 40% risk reduction in death for Signatera-positive patients. Celebrex improved disease-free and ...
Benzinga.com

Data Presented at ASCO Shows Natera's Signatera Test Detects Immunotherapy Treatment Response in Metastatic Cancers

SAN CARLOS, Calif., June 3, 2019 /PRNewswire/ -- A new study demonstrates the ability of Natera's Signatera™ test to assess patient response to immunotherapy in the metastatic setting across multiple ...

Natera’s Stronghold in Cancer Recurrence Tests Prompts Wood’s Ark to Expand Stake

Natera’s flagship product, Signatera is a personalized MRD blood test that detects cancer recurrence by identifying the ...
Insider Monkey

Signatera Oncology Test Drives Natera’s (NTRA) Growth

Carillon Tower Advisers, an investment management company, released its fourth-quarter 2025 investor letter for the “Carillon Eagle Mid Cap Growth Fund”. A copy of the letter can be downloaded here.